ASPNAspen Aerogels, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~0% a year FCF growth. Roughly in line with its three-year revenue growth of 2% a year.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ASPN's price assumes
Aspen Aerogels, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.23× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 7.4%
Free cash flow yield · Building Products & Equipment median 6.3%
- Growth the price implies
- +0.47%
Growth the price implies · The price pays for +0.47% free cash flow growth a year for a decade; revenue has grown +2.1% a year over the last three.
- Price / book
- 1.33
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 1.33
- EV / EBIToperating margin −61%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 0.74
- Free cash flow, trailing twelve months
- $34M
- Market capitalisation
- $466M
- 3-year revenue growth
- +2.1%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Building Products & Equipment
Ranks #18 of 19 by RyuScore